본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

고급검색

인명/단체명

저자정보 상세정보
인명/단체명을 입력하세요.

키워드

  • 대표어

  • 외국어

-

초록보기

This study aims to explore solutions to address access to medicines (A2M) for cancer or severe disease patients, particularly focusing on the challenges of coverage gaps and non-listed medicines in South Korea. To achieve this, the life cycle-based A2M frameworks of France, Scotland, and Australia were analyzed. The findings revealed that these countries maintained the principles of drug reimbursement while enhancing access to anticancer and orphan drugs through the Named-Patient Approach (NPA) and Dedicated Funds. To ensure access during the coverage gap period, each country operated specific programs: AAP in France, IPTR and PACS Tier 2 in Scotland, and IPU in Australia. Additionally, for non-listed but high-cost drugs such as ultra-orphan drugs, mechanisms such as Liste en Sus (France), PACS Tier 1 (Scotland), and LSDP and HST Addendum (Australia) were implemented, commonly supported through dedicated funding to ensure continued patient access. The NPA complemented collective reimbursement systems by providing a more tailored and inclusive A2M framework. In contrast, South Korea lacks these structures, leading to efforts to expedite the drug evaluation process or introduce bypass mechanisms to increase drug listing. Additionally, policies such as “Use first, Assess later” have been proposed, which risk undermining the principles of evidence-based drug evaluation and cost-effectiveness assessment. To enhance A2M in South Korea, two key recommendations were proposed in this study. First, introducing the NPA to accommodate individual patients needs. Second, establishing a dedicated fund supported by pharmaceutical manufacturers’ contributions to enable financial support during the coverage gaps and for non-listed drugs. This approach might preserve the principles of the Positive List System while ensuring a more comprehensive and equitable A2M framework. Moreover, formalizing pharmaceutical manufacturers’ patient assistance programs through a structured approach would enhance equity by shifting the focus from product-based assistance to needs-based support. Ultimately, broad societal consensus—through stakeholder engagement, policy discussions, and public awareness—will be essential for implementing these policy changes.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Assessment of the excess risk of avoidable hospitalization for ambulatory-care sensitive conditions in patients with depression = 우울증 환자의 외래진료 민감 질환으로 인한 입원의 위험 평가 : 전국 인구 기반 연구 : a population-based national study Yekyong Kim, Hye-Young Kang p. 15-23
해외 유명인 언급과 소셜 미디어를 통해 발생한 국내 대중의 비만치료제 관심도와 반응 분석 = Analysis of domestic public interest and reactions to obesity medications driven by international celebrity mentions and social media 황지현, 김성옥, 이지원, 한은아 p. 24-31
중증질환 치료제의 접근성 강화 = Enhancing access to medicines through the named patient approach and dedicated funding : insights from France, Scotland, and Australia : 개별환자접근방식과 별도기금 도입의 필요성 권혜영 p. 1-14
국내 항생제 사용관리 프로그램의 최적화 방향에 대한 제언 = Suggestions for optimizing the antimicrobial stewardship program in South Korea : with reference to ASP initiatives in the US and Japan : 미국 및 일본의 사례를 참고하여 김도연, 김조안, 윤지용, 정지수, 홍송희 p. 32-44
의료용 마약류 빅데이터(NIMS)를 활용한 의료용 마약류 약물의 처방 경향 및 처방량 관련 요인 분석 = Analysis of prescription patterns and factors related to prescription volume of medical narcotics using the narcotics information management system (NIMS) 안은지, 하동문, 이의경 p. 45-52

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차

권호

기사명 원문보기 기사목차
닫기